Photo: Mint Markets
Business & Finance
Sun Pharma shares gain despite Q2 profit slips 36% YoY | Should you buy, sell or hold? What brokerage says, target price
TL;DR
- 5 crore. 7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Nov 1, 2026 · Updated 11/1/2026, 12:20:25 PM · Reported with: Mint Markets
Sources (1)
NRI Bytes writes its own articles from the reporting below.
Mint Markets — Sun Pharma shares gain despite Q2 profit slips 36% YoY | Should you buy, sell or hold? What brokerage says, target priceUp next · Business & Finance
The Liver Doc lambasts Deepinder Goyal as ‘rage’ mounts over ₹85,000 Temple device: 'Bad science', ‘scam’
Read next →
More stories
Business & Finance
Diwali, Chhath 2026: Delhi Police traffic advisory for Anand Vihar ISBT till Nov 15; what UP, Bihar passengers must know
1h ago
Business & Finance
Will banks remain closed for Dhanteras, Diwali and other festivals; check list
1h ago
Business & Finance
Beyond gold: What $340 billion in crypto flows says about India's investment preferences this Dhanteras
1h ago
Business & Finance
Diwali Fairy Lights, Nails And Wires On Trees In Thane Spark Row, TMC Files Police Complaint
1h ago
